Testing a new antibody drug for moderate to severe pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old with a confirmed diagnosis of pemphigus.
- Your pemphigus is moderate to severe, meaning it affects a large area of your skin or causes many blisters.
- You have not tried this study drug (CM313) before, even if other treatments like rituximab didn't work well.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have active infections like HIV, hepatitis B or C, or other serious infections.
- You have not had certain treatments (like cyclophosphamide) in the last 8 weeks or rituximab in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a structured lifestyle program (diet and exercise) can improve quality of life for people with pemphigus, a chronic blistering skin condition. If you have pemphigus, this could help you feel better day-to-day.
This study tests a new medicine called CM313 for people with moderate to severe pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if CM313 can help reduce these blisters and improve quality of life.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study compares two treatments for moderate-to-severe pemphigus vulgaris, a rare skin blistering condition. One group gets rituximab plus corticosteroids, the other gets corticosteroids plus azathioprine. It aims to find which combination works better to control the disease with fewer side effects.
Hear when a new Pemphigus Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.